Fallon L - Search Results

1

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.

Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. Dougados M, et al. Among authors: fallon l. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478. RMD Open. 2022. PMID: 36814062 Free PMC article. Clinical Trial.

2

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Burmester GR, Coates LC, Cohen SB, Tanaka Y, Vranic I, Nagy E, Lazariciu I, Chen AS, Kwok K, Fallon L, Kinch C. Burmester GR, et al. Among authors: fallon l. Rheumatol Ther. 2023 Oct;10(5):1255-1276. doi: 10.1007/s40744-023-00576-8. Epub 2023 Jul 17. Rheumatol Ther. 2023. PMID: 37458964 Free PMC article.

3

Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis.

Deodhar A, Marzo-Ortega H, Wu J, Wang C, Dina O, Kanik KS, Fallon L, Gensler LS. Deodhar A, et al. Among authors: fallon l. ACR Open Rheumatol. 2023 Dec;5(12):632-643. doi: 10.1002/acr2.11601. Epub 2023 Sep 29. ACR Open Rheumatol. 2023. PMID: 37775977 Free PMC article.

4

Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies.

Menon S, Shoji S, Tsuchiwata S, Fallon L, Kanik K. Menon S, et al. Among authors: fallon l. J Clin Pharmacol. 2024 Oct 25. doi: 10.1002/jcph.6147. Online ahead of print. J Clin Pharmacol. 2024. PMID: 39453735

5

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib.

Kristensen LE, Strober B, Poddubnyy D, Leung YY, Jo H, Kwok K, Vranic I, Fleishaker DL, Fallon L, Yndestad A, Gladman DD. Kristensen LE, et al. Among authors: fallon l. Ther Adv Musculoskelet Dis. 2023 Feb 7;15:1759720X221149965. doi: 10.1177/1759720X221149965. eCollection 2023. Ther Adv Musculoskelet Dis. 2023. PMID: 36777695 Free PMC article.

6

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Burmester GR, Coates LC, Cohen SB, Tanaka Y, Vranic I, Nagy E, Lazariciu I, Chen AS, Kwok K, Fallon L, Kinch C. Burmester GR, et al. Among authors: fallon l. Rheumatol Ther. 2024 Feb;11(1):221-222. doi: 10.1007/s40744-023-00615-4. Rheumatol Ther. 2024. PMID: 38041731 Free PMC article. No abstract available.

7

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Young P, Fallon L, Mundayat R, Dina O, Blachley T, Middaugh N, Ogdie A. Mease PJ, et al. Among authors: fallon l. Rheumatol Ther. 2024 Apr;11(2):313-329. doi: 10.1007/s40744-023-00631-4. Epub 2024 Jan 22. Rheumatol Ther. 2024. PMID: 38252211 Free PMC article.

8

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.

Nash P, Mease PJ, Fleishaker D, Wu J, Coates LC, Behrens F, Gladman DD, Kivitz AJ, Wei JC, Shirinsky I, Menon S, Romero AB, Fallon L, Hsu MA, Wang C, Kanik KS. Nash P, et al. Among authors: fallon l. Lancet Rheumatol. 2021 Jan;3(1):e28-e39. doi: 10.1016/S2665-9913(20)30339-8. Epub 2020 Nov 16. Lancet Rheumatol. 2021. PMID: 38273637

9

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.

Nash P, Coates LC, Fleishaker D, Kivitz AJ, Mease PJ, Gladman DD, FitzGerald O, Wang C, Wu J, Hsu MA, Menon S, Fallon L, Kanik KS. Nash P, et al. Among authors: fallon l. Lancet Rheumatol. 2021 Apr;3(4):e270-e283. doi: 10.1016/S2665-9913(21)00010-2. Epub 2021 Mar 24. Lancet Rheumatol. 2021. PMID: 38279411

10

Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.

Kristensen LE, Deodhar A, Leung YY, Vranic I, Mortezavi M, Fallon L, Yndestad A, Kinch CD, Gladman DD. Kristensen LE, et al. Among authors: fallon l. Rheumatol Ther. 2024 Jun;11(3):487-499. doi: 10.1007/s40744-024-00662-5. Epub 2024 May 2. Rheumatol Ther. 2024. PMID: 38696034 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters